PhaseBio settles SFJ dispute in Ch.11; $2.5M admin claim, $27.8M unsecured claims

PhaseBio Pharmaceuticals Inc

Settlement stipulates a $2.5M allowed administrative claim for SFJ, down from the $15.4M sought.
SFJ receives $27.8M in aggregate general unsecured claims under the settlement.
Plan requires sale of Bentracimab royalties within six months of BLA approval; if sale <$2.5M, royalty transfers to SFJ.
SFJ will withdraw its objection and support the amended Chapter 11 Plan after Bankruptcy Court approval.
November 2023 monthly report shows cash $2.55M, cumulative professional fees $14.2M, zero employees.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PhaseBio Pharmaceuticals Inc entered into Plan Support and Settlement Agreement with SFJ Pharma X, Inc. (effective 2024-03-06).

Action: entry
Agreement: settlement
Counterparty: SFJ Pharma X, Inc.
Effective: 2024-03-06

Exact text from the filing

On March 6, 2024, the Company and SFJ executed and entered into a Plan Support and Settlement Agreement (the “Settlement Agreement”) to resolve the Motion to Allow, the Objection, and related matters.

View on SEC.gov

565 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-24-065935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.